Taysha Gene Therapies, Inc. TSHA
4.67
(0.12)
(2.51%)
as of 25 Sep
- Market cap
- $1.6B
- P/E
- 0.0×
Follow TSHA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(64.93%) | (68.45%) | (97.28%) | (47.05%) | |
| (40.23%) | (43.28%) | (59.21%) | (37.23%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(35.93%) | (35.76%) | (48.35%) | (34.17%) | |
Average Days of Receivables |
— | 0.00 | — | — | |
Free Cash Flow per Share |
(0.24) | (0.29) | (0.32) | (0.38) | |
Free Cash Flow |
(85.16) | (93.83) | (118.83) | (139.07) | |
Capital Expenditures |
(0.49) | (0.74) | (6.88) | (6.88) | |
Piotroski F-Score |
— | 3.00 | — | — | |
| Other line items | |||||
Cash ROIC |
(14.92%) | (15.08%) | (20.81%) | (14.82%) | |
Accounts Receivable Turnover |
— | 0.00 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 732.54% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 287.14% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 112.74% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.85 | 0.85 | 0.86 | 0.88 | |
Depreciation/Fixed assets |
0.17 | 0.17 | 0.18 | 0.49 | |
Capex/Depreciation |
(0.42) | (0.64) | (5.95) | (5.88) | |
Revenue per Share |
0.00 | 0.04 | 0.00 | 0.00 | |
Operating CF per Share |
(0.24) | (0.29) | (0.31) | (0.36) | |
Capex per Share |
0.00 | 0.00 | (0.02) | (0.02) | |
Capex to Sales |
0.00 | 0.06 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | (924.08%) | 0.00% | 0.00% |
Columns are period end dates